Interleukin-4 (IL-4) signaling, drug efflux proteins, and the upregulation of aldehyde dehydrogenase (ALDH) activity are all known to be associated with the resistance of CSCs to conventional cancer therapies [107]. This evidence concerns the gene IL4 and cancer.